Tango Therapeutics: president R&D Crystal Adam sold 27,000 shares

What happened Crystal Adam, president, R&D, exercised options for 27,000 shares at $5.20 per share for a total exercise cost of $140,400 and sold 26,400 shares at a weighted average price of $24.45 for $645,604 and 600 shares at $25.32 for $15,192, all on Oct 1, 2026. The filing also reports a derivative disposition of 27,000 shares at $0.00.

Key details

• Transaction dates and prices:
  • Oct 1, 2026 — Exercise/conversion (code M): 27,000 shares acquired at $5.20, $140,400.
  • Oct 1, 2026 — Sale (code S): 26,400 shares disposed at weighted average $24.45, $645,604 (prices ranged $23.96 to $24.95 per share; see footnote).
  • Oct 1, 2026 — Sale (code S): 600 shares disposed at weighted average $25.32, $15,192 (prices ranged $25.04 to $25.41 per share; see footnote).
  • Oct 1, 2026 — Exercise/conversion (code M, derivative): 27,000 shares disposed at $0.00, $0.
• Shares owned after the transaction: not stated in the provided filing data.
• Footnotes of note:
  • F1: Transactions were effected under a Rule 10b5-1 trading plan adopted Oct 27, 2025.
  • F2/F3: Weighted average sale prices are reported; per-share sale price ranges are provided in the footnotes and full price-by-price detail is available on request to the SEC staff, the issuer, or a security holder.
  • F4: The option vests over four years, 25% on Feb 27, 2024, then monthly over 36 months.
• Filing date and timeliness: Form filed Oct 5, 2026 for transactions on Oct 1, 2026 (filed within the two-business-day Form 4 deadline).

Why it may matter

• The filing shows an exercise of options for 27,000 shares and sales of 27,000 shares on the same date, meaning the exercised shares were sold contemporaneously.
• This is an insider executive transaction; the filing does not show post-transaction holdings in the provided data.
• This filing does not show why the insider traded or why the company acted.